Goldman Sachs Group Inc Biotechnology

Goldman Sachs Group Inc

$596 Billion
Q1 2025

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
ATOS Atossa Therapeutics, Inc.	$109M	$125,000 0.0% of portfolio	187,927	Q1 2025 Reduced 45.51%
ATNM Actinium Pharmaceuticals, Inc.	$42.3M	$123,000 0.0% of portfolio	76,811	Q1 2025 Reduced 43.23%
TNYA Tenaya Therapeutics, Inc.	$24.8M	$120,000 0.0% of portfolio	211,171	Q1 2025 Reduced 30.99%
PRLD Prelude Therapeutics Inc	$36.4M	$119,000 0.0% of portfolio	155,215	Q1 2025 Added 4.64%
HOWL Werewolf Therapeutics, Inc.	$40.8M	$108,000 0.0% of portfolio	111,985	Q1 2025 Reduced 21.04%
PMVP Pmv Pharmaceuticals, Inc.	$43.3M	$98,000 0.0% of portfolio	90,263	Q1 2025 Reduced 25.55%
VIGL Vigil Neuroscience, Inc.	$224M	$98,000 0.0% of portfolio	55,566	Q1 2025 Reduced 78.35%
IKNA Ikena Oncology, Inc.	$50.8M	$97,000 0.0% of portfolio	76,464	Q1 2025 Added 62.36%
STTK Shattuck Labs, Inc.	$48.3M	$97,000 0.0% of portfolio	102,313	Q1 2025 Reduced 57.52%
IPSC Century Therapeutics, Inc.	$33M	$86,000 0.0% of portfolio	179,635	Q1 2025 Added 26.88%
CGEN Compugen LTD	$152M	$85,000 0.0% of portfolio	58,268	Q1 2025 Reduced 83.18%
AUTL Autolus Therapeutics PLC	$218M	$78,000 0.0% of portfolio	50,411	Q1 2025 Reduced 60.06%
SLN Silence Therapeutics PLC	$198M	$68,000 0.0% of portfolio	24,375	Q1 2025 Reduced 33.92%
XFOR X4 Pharmaceuticals, Inc	$272M	$65,000 0.0% of portfolio	273,865	Q1 2025 Reduced 42.66%
ANEB Anebulo Pharmaceuticals, Inc.	$27.7M	$62,000 0.0% of portfolio	47,954	Q1 2025 New
VOR Vor Biopharma Inc.	$8.37M	$61,000 0.0% of portfolio	84,945	Q1 2025 Added 218.17%
ONCY Oncolytics Biotech Inc	$19.7M	$60,000 0.0% of portfolio	109,098	Q1 2025 Added 7.59%
PEPG Pep Gen Inc.	$36.2M	$56,000 0.0% of portfolio	40,240	Q1 2025 Reduced 59.08%
MCRB Seres Therapeutics, Inc.	$923M	$52,000 0.0% of portfolio	74,629	Q1 2025 Added 40.94%
LYRA Lyra Therapeutics, Inc.	$951M	$48,000 0.0% of portfolio	370,194	Q1 2025 Reduced 33.36%
UNCY Unicycive Therapeutics, Inc.	$11.4M	$41,000 0.0% of portfolio	73,475	Q1 2025 Reduced 0.18%
CTMX Cytom X Therapeutics, Inc.	$171M	$39,000 0.0% of portfolio	61,719	Q1 2025 New
OVID Ovid Therapeutics Inc.	$22.5M	$32,000 0.0% of portfolio	104,435	Q1 2025 Reduced 47.29%
RLMD Relmada Therapeutics, Inc.	$23.5M	$32,000 0.0% of portfolio	120,852	Q1 2025 New
VXRT Vaxart, Inc.	$50.6M	$31,000 0.0% of portfolio	76,156	Q1 2025 New
ELEV Elevation Oncology, Inc.	$6.99M	$19,000 0.0% of portfolio	76,646	Q1 2025 Reduced 95.36%
CUE Cue Biopharma, Inc.	$23M	$13,000 0.0% of portfolio	14,401	Q1 2025 Reduced 58.29%
GALT Galectin Therapeutics Inc	$76.7M	$13,000 0.0% of portfolio	10,699	Q1 2025 Reduced 77.49%
KRON Kronos Bio, Inc.	$49.4M	$10,000 0.0% of portfolio	12,238	Q1 2025 Reduced 32.17%
FGEN Fibrogen Inc	$29.1M	$9,000 0.0% of portfolio	32,203	Q1 2025 Reduced 28.92%
IMAB I Mab	$190M	$8,000 0.0% of portfolio	10,685	Q3 2024 Reduced 32.16%
PASG Passage Bio, Inc.	$26.1M	$4,000 0.0% of portfolio	11,596	Q1 2025 Reduced 57.16%
ADAP Adaptimmune Therapeutics PLC	$47.4M	$3,000 0.0% of portfolio	16,149	Q1 2025 Reduced 0.07%
SBTX Silverback Therapeutics, Inc.	$0	$0 0.0% of portfolio	717,953	Q1 2025 Reduced 18.98%

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.